[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Intercommunal Robert Ballanger\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,71,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640873","coercive-control-and-intimate-partner-violence-100640873",false,"NCT07578194","Coercive Control and Intimate Partner Violence","Coercive Control and Intimate Partner Violence: Examining the Relationships Between Exposure to Violence and Victims' Physical and Mental Health Outcomes","CCVCS","Inclusion Criteria:\n\n* Women aged 18 years and older, who have experienced an intimate partner relationship involving violence for at least three months (currently in the relationship or separated).\n* Women identified as victims of intimate partner violence.\n* Sufficient proficiency in French to complete self-administered questionnaires and participate in interviews.\n* No objection to participation in the study (non-opposition).\n* Affiliation with a French social security scheme or eligibility for universal health coverage (Couverture Maladie Universelle, CMU).\n\nExclusion Criteria:\n\n* Individuals under legal protection in accordance with the French Public Health Code (Articles L.1121-5 to L.1121-8 and L.1122-1-2), with the exception of pregnant or breastfeeding women.\n* Cognitive impairment or severe intellectual disability preventing comprehension of the questionnaires.\n* Severe and unstable psychiatric disorders (e.g., schizophrenia, delusional disorders, acute bipolar disorder).","FEMALE","18 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"NA","Coercive control (CC) is increasingly recognized as a central component of intimate partner violence (IPV) and a major determinant of victims' health outcomes. While widely integrated into policy and legal frameworks in several countries, CC remains insufficiently explored in the French research context, particularly regarding its clinical and psychopathological dimensions. This gap may limit the identification of victims and the provision of appropriate care.\n\nThe present study aims to investigate the association between exposure to coercive control and physical and mental health outcomes among victims of intimate partner violence. By improving the understanding of CC-related health impacts, this research seeks to support better identification of high-risk situations and inform clinical and public health interventions.",[27],"Coercive Control",[29],"partner violence","NOT_YET_RECRUITING","2026-05-21",{"date":33,"type":34},"2026-05-26","ACTUAL",{"date":36,"type":21},"2026-05-30",{"date":38,"type":21},"2028-05-30",{"name":40,"class":41},"Centre Hospitalier Intercommunal Robert Ballanger","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100589316","evaluation-of-a-diva-score-effectiveness-at-admission-for-preserving-venous-capital-in-patients-with-difficult-access-100589316","NCT06952829","Evaluation of A-DIVA Score Effectiveness at Admission for Preserving Venous Capital in Patients With Difficult Access","Randomized Controlled Clinical Trial Assessing the Effectiveness of a Venipuncture Strategy Adapted According to A-DIVA Score Results Compared to Standard Care in Reducing the Number of Punctures","ERV-ADIVA","Inclusion Criteria:\n\n* Male and Female Adult Patients Aged 18 Years and Older\n* written informed consent given by patient\n* Affiliation to a social security system or equivalence system\n\nExclusion Criteria:\n\n* Patients in Intensive Care Units\n* Patients with Psychiatric Disorders or Under Psychiatric Care\n* Minor Patients Under 18 Years of Age\n* Pregnant or Breastfeeding Women\n* Vulnerable and Protected Individuals as Defined by the Public Health Code (Articles L.1121-5 to L.1121-8 and L.1122-1-2)\n* Patients Participating in Another Interventional Study\n* Dying patients\n* Patients Receiving Infusions of:\n\n  * Chemotherapy Drugs with a pH \\\u003C5 or \\>8\n  * Solutions with an Osmolarity \\>900 mOsm\u002FL\n* Patients refusing to participate in the study","ALL",{"count":53,"type":21},600,[24],"In certain cases (e.g.: patient who are difficult to perfuse, thin veins, etc.), an increase in venipunctures performed by study nurses in healthcare services can lead to a loss of venous capital, repeated pain during punctures, discontinuous treatment follow-up and numerous requests for assistance from colleagues, including nurse anesthetists, but often too late.\n\nThe main objective of project is to reduce the number of punctures to access the venous system after evaluation of adult patients upon entering the hospitalization department using the A-DIVA tool. the A-DIVA score predicts the difficulty in infusing an adult patient",[57,58,59],"Internal Medicine","Surgery","Neurology",[61,62],"Adult-Difficult IntraVenous Access (A-DIVA)","capital venous preservation","2025-04-28",{"date":65,"type":34},"2025-05-01",{"date":67,"type":21},"2025-04-21",{"date":69,"type":21},"2028-09",{"name":40,"class":41},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":51,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100550149","evaluation-of-the-videodrama-therapeutic-device-for-children-with-autism-spectrum-disorders-100550149","NCT06443320","Evaluation of the Videodrama Therapeutic Device for Children With Autism Spectrum Disorders","VIDEOTSA","Inclusion Criteria:\n\n* Children aged 3 to 15 years.\n* Clinically confirmed ASD by a psychiatrist.\n* Parental or legal guardian consent for participation.\n* Child showing a strong interest in screens and\u002For video content.\n* Ability to tolerate the presence of other children.\n* Minimum of 18 video drama sessions.\n* Not having benefited from disease care in the past.\n* Affiliation to a social security system\n\nExclusion Criteria:\n\n* No ASD diagnosis.\n* Younger than 3 or older than 15 at the study start.\n* No interest in screens or video content.\n* Parental or legal guardian refusal for participation.\n* Dropping out before completing 18 sessions.\n* Patient having benefited a disease care in the past","3 Years","15 Years",{"count":81,"type":21},30,[24],"Autism spectrum disorder (ASD) is a neurodevelopmental disorder (Valerie, Sperenza, 2009) that begins early in development, characterized by persistent deficits in communication and social interactions across various contexts and restricted, repetitive patterns of behavior, interests, or activities. These symptoms significantly impact social, school\u002Fprofessional functioning, or other important areas and are not better explained by intellectual disability or global developmental delay (American Psychiatric Association, 2013).",[85],"Autism Spectrum Disorder (ASD)",[87,88],"autism","videodrama","RECRUITING","2025-02-04",{"date":92,"type":34},"2025-02-06",{"date":94,"type":34},"2023-12-04",{"date":96,"type":21},"2027-03-04",{"name":40,"class":41},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100479220","influence-of-preoperative-immunomodulation-by-oral-impact-on-postoperative-complications-following-cystectomies--nephrectomies-100479220","NCT05520151","Influence of Preoperative Immunomodulation by Oral Impact on Postoperative Complications Following Cystectomies & Nephrectomies","Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies","IMPACTURO","Inclusion Criteria:\n\n* 18 years of age and older\n* Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies.\n* Having expressed their free and informed consent.\n* Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Immune deficiency.\n\n  * HIV infection.\n  * Curative surgery for chronic urinary tract infection.\n  * Urgent surgery.\n  * Inability to take oral impact 7 days before surgery.\n  * Unstable psychiatric state.\n  * Infection with COVID 19 during postoperative stay.",{"count":107,"type":21},214,[24],"any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.",[111],"Urological Manifestations",[113,114,115,116],"cystectomy,","nephrectomy,","laparotomies","reduction of postoperative complications","2024-07-11",{"date":119,"type":34},"2024-07-15",{"date":121,"type":34},"2022-11-30",{"date":123,"type":21},"2025-06",{"name":40,"class":41},2,""]